- Home
- CEP vs RLAY Comparison
CEP vs RLAY Comparison
Compare CEP & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- RLAY
- Stock Information
- Founded
- CEP 2020
- RLAY 2015
- Country
- CEP United States
- RLAY United States
- Employees
- CEP N/A
- RLAY N/A
- Industry
- CEP
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEP
- RLAY Health Care
- Exchange
- CEP NYSE
- RLAY Nasdaq
- Market Cap
- CEP 368.0M
- RLAY 576.1M
- IPO Year
- CEP 2024
- RLAY 2020
- Fundamental
- Price
- CEP $26.23
- RLAY $3.51
- Analyst Decision
- CEP
- RLAY Strong Buy
- Analyst Count
- CEP 0
- RLAY 11
- Target Price
- CEP N/A
- RLAY $18.40
- AVG Volume (30 Days)
- CEP 726.7K
- RLAY 1.6M
- Earning Date
- CEP 01-01-0001
- RLAY 08-05-2025
- Dividend Yield
- CEP N/A
- RLAY N/A
- EPS Growth
- CEP N/A
- RLAY N/A
- EPS
- CEP 0.25
- RLAY N/A
- Revenue
- CEP N/A
- RLAY $7,679,000.00
- Revenue This Year
- CEP N/A
- RLAY $14.31
- Revenue Next Year
- CEP N/A
- RLAY N/A
- P/E Ratio
- CEP $110.08
- RLAY N/A
- Revenue Growth
- CEP N/A
- RLAY N/A
- 52 Week Low
- CEP $9.99
- RLAY $1.78
- 52 Week High
- CEP $59.75
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- RLAY 56.86
- Support Level
- CEP N/A
- RLAY $3.10
- Resistance Level
- CEP N/A
- RLAY $3.53
- Average True Range (ATR)
- CEP 0.00
- RLAY 0.23
- MACD
- CEP 0.00
- RLAY 0.00
- Stochastic Oscillator
- CEP 0.00
- RLAY 75.21
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).